Suggested reading about KL-6 (Krebs von den Lungen-6)


We have assembled a list of the most relevant publications about the clinical interest of using KL-6 as a biomarker:

  1. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
    J Intern Med (2006 Nov) 260(5):429-34
  2. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.
    Respirology (2006 Mar) 11 (2):164-8
  3. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases.
    Intern Med 50: 2889-2892, 2011
  4. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation.
    The Journal of Heart and Lung Transplantation (2011 Dec) 30:12
  5. Utility  of KL-6/MUC1 in the clinical management of interstitial lung diseases.
    Respiratory Investigation (2012) 50:3-13
  6. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Respiratory Medicine (2013) 107, 1431-1437
  7. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.
    Respiratory Medicine (2014) 108, 1031-1039

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.